{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-332809","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2026-08-04T20:10:16+00:00","discovered_at":"2026-08-04T20:11:03.450144+00:00","generated_at":"2026-08-04T20:11:08.861746+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"OnKure Q2 2026 net loss $15.3M; cash $176.4M funds operations into 2029","bullets":["Net loss of $15.3M ($0.31 per share) vs $15.4M ($1.14 per share) in Q2 2025.","Cash, cash equivalents and marketable securities of $176.4M as of June 30, 2026; runway into 2029.","R&D expenses flat at $12.6M; G&A up $0.6M to $4.3M on higher personnel and consulting costs.","IND submissions for PI3Kα pan-mutant candidates OKI-345 (breast cancer) and OKI-355 (vascular anomalies) planned for 1H 2027.","Hosted KOL event on PI3Kα selectivity; participated as exhibitor/sponsor at ISSVA World Congress 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-332809","json":"https://secwatch.observer/filing/0001193125-26-332809.json","markdown":"https://secwatch.observer/filing/0001193125-26-332809.md","text":"https://secwatch.observer/filing/0001193125-26-332809.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000119312526332809/0001193125-26-332809-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000119312526332809/okur-20260804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T20:11:08.861746+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}